Stock market announcement archive

LIFE: Satisfied with the final results of the Rights Issue

June 14, 2024
Bergen, Norway, 14 June, 2024: Today, Lifecare ASA (LIFE), a clinical stage medical sensor company developing the next generation Continuous Glucose Monitor (CGM), announces that all valid subscriptions from investors with subscription rights have been allocated in accordance with the allocation criteria set out in the prospectus for the Rights Issue. Reference is made to […]
Read more

LIFE – Improved read out distance for sensor – preparing for longevity trials in dogs

June 10, 2024
Bergen, Norway, June 10th, 2024: Today, Lifecare ASA (LIFE), a clinical stage medical sensor company developing the next generation Continuous Glucose Monitor (CGM), announces that the company have improved the read-out distance from sensor to the read-out device. Reference is made to previous communications in the Q1 reporting regarding the need to improve the read-out […]
Read more

Minutes from Annual General Meeting

April 30, 2024
The Annual General Meeting of Lifecare AS was convened as a hybrid meeting on 30 April 2024. Trine Teigland (Board member) and Lutz Heinemann (Board member) were re-elected and Tone Kvåle (Board member) was elected as new member of the BoD as proposed by the Nomination Committee. No alternative candidates were proposed. All proposals on […]
Read more

LIFE – Lifecare becomes majority shareholder in RemovAid

April 29, 2024
Bergen, Norway, 29 April 2024: Lifecare AS (LIFE), a clinical stage medical sensor company developing the next generation Continuous Glucose Monitor (CGM), have invested NOK 2 million through a private placement in RemovAid AS, a medical technology company based in Oslo, Norway, after which Lifecare holds 81.1% of the shares in RemovAid. RemovAid has developed […]
Read more

LIFE – Strategic investment in RemovAid AS

April 26, 2024
Bergen, Norway, 26th April 2024: Lifecare AS (LIFE), a clinical stage medical sensor company developing the next generation Continuous Glucose Monitor (CGM), intend to invest NOK 2 million and become the majority shareholder in RemovAid AS, a medical technology company based in Oslo, Norway. RemovAid is an ISO 13485 certified company who specializes in the […]
Read more

LIFE: Lifecare BoD propose a partially underwritten rights issue

April 26, 2024
Bergen, Norway, 26 April 2024: Lifecare AS (LIFE), a clinical stage medical sensor company developing the next generation Continuous Glucose Monitor (CGM), intent to invite its existing shareholders in a NOK 90 million partially underwritten rights issue. The proposed rights issue will ensure preferential subscription rights for existing shareholders, with already underwritten guarantees a minimum […]
Read more

LIFE: Presentation at MARSS 2024

April 16, 2024
Lifecare’s Dr. Preeti Sharma is invited as a speaker to present a paper at International Conference on Manipulation, Automation and Robotics at Small Scales (MARSS 2024) in Delft, Netherlands. The paper “Towards Scanning Electron Microscope (SEM) automation” is accepted by the MARSS 2024 Organization Committee and assigned for an oral presentation at the conference in […]
Read more

LIFE – Lifecare’s Annual Report 2023

April 9, 2024
Bergen, Norway, April 9th, 2024: Today, Lifecare AS (LIFE) (the “Company”), a clinical stage medical sensor company developing the next generation Continuous Glucose Monitor (CGM), publishes Annual Report 2023. – The technology development and company progress were fantastic in 2023. We expect nothing less in 2024, in our mission to make life easier for patients […]
Read more

LIFE – Breakthrough: Reaching target for pilot production

April 3, 2024
Bergen, Norway, 3rd April 2024: Lifecare AS (LIFE), a clinical stage medical sensor company developing the next generation Continuous Glucose Monitor (CGM), has successfully reached the target for pilot production of the Sencell sensor. Reports show a breakthrough, and this will pave the way for the automated production by end of Q2 as scheduled. Reference […]
Read more

LIFE: The European Patent Office issues a new Lifecare patent

March 21, 2024
Bergen, Norway, March 21st, 2024: Today, Lifecare AS (LIFE), a clinical stage medical sensor company developing the next generation Continuous Glucose Monitor (CGM), announces that the European Patent Office (EPO) has notified that they will grant for a new patent to Lifecare. Reference is made to stock exchange notification November 8th, 2023, that EPO intended […]
Read more